There are no generic versions of Ilumya currently available. Ilumya, also known by its generic name tisafeletumab, is a biologic drug used to treat moderate to severe plaque psoriasis [1].
When will Ilumya's patent expire?
The patent protection for Ilumya is a complex area. According to DrugPatentWatch.com, the listed patent expiry dates vary, but some key patents are expected to expire around 2032 [2]. However, patent landscapes can change due to ongoing legal challenges and exclusivities.
Who makes Ilumya?
Ilumya is manufactured by LEO Pharma [1].
What are the alternatives to Ilumya for plaque psoriasis?
Several other treatment options exist for moderate to severe plaque psoriasis, including other biologic drugs and traditional systemic therapies. These alternatives may include other interleukin inhibitors, tumor necrosis factor (TNF) inhibitors, or phosphodiesterase-4 (PDE4) inhibitors [3]. The choice of treatment depends on individual patient factors and medical guidance.
Can biosimilars of Ilumya be developed?
As a biologic drug, Ilumya is eligible for biosimilar development once its exclusivity and patent protections expire. Biosimilars are highly similar to the reference biologic product and aim to offer comparable efficacy and safety profiles. The development and approval process for biosimilars are regulated to ensure they meet rigorous standards [4].
What is tisafeletumab?
Tisafeletumab is the active pharmaceutical ingredient in Ilumya. It is a monoclonal antibody that targets the interleukin-23 (IL-23) pathway, a key driver of inflammation in psoriasis [1].